Boston Scientific's Apex PTCA dilatation catheter receives FDA approval

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Boston Scientific reported that it has received approval from the U.S. Food and Drug Administration to market its Apex percutaneous transluminal coronary angioplasty (PTCA) dilatation catheter.

The device is a pre-dilatation balloon catheter developed specifically to address physicians' needs in treating challenging atherosclerotic lesions, Boston Scientific said. It is available for distribution in both Monorail and Over-The-Wire catheter platforms, according to the company.